Dr Kumar Bishwajit Sutradhar
Ph.D. in Biomedical Engineering (UNSW Sydney)
M. Pharm. Tech. (UAP), B. Pharm. (SUB)
WELCOME
Dr Kumar Bishwajit Sutradhar is an esteemed academic and accomplished researcher specializing in pharmaceutical formulation technology and biomedical engineering. With a distinguished background as a PhD graduate from the prestigious University of New South Wales (UNSW), Australia, his expertise lies in developing and utilising surface-engineered cerium oxide nanoparticles for precise and targeted delivery of cancer therapeutics. Dr Sutradhar is proficient in nanomaterial synthesis, characterization, and the application of advanced drug delivery systems for cancer treatment.
​
As a recognized authority in the field, Dr Sutradhar has made significant contributions to the scientific community. His groundbreaking thesis on surface-engineered cerium oxide nanoparticles for target-specific cancer drug delivery has earned him accolades and has enhanced our understanding of innovative approaches to combat cancer. His research encompasses diverse aspects of nanotechnology, pharmaceutical sciences, and biomedical engineering, positioning him at the forefront of cutting-edge advancements in these disciplines.
RESEARCH
INTEREST
NANOMATERIAL SYNTHESIS & FABRICATION
BIOENGINEERING OF DRUGS & THERAPEUTICS
TARGET SPECIFIC DRUG DESIGN & DELIVERY
CURRENT
RESEARCH
Surface-engineered cerium oxide nanoparticles show promise for targeting CD44-expressing cancer cells.
Cerium oxide nanoparticles (CNPs or nanoceria) are an interesting group of simple metal oxide nanoparticles (NPs) in that they possess unusual, but useful redox chemistry properties for industrial applications such as catalysts, fuel additives, and polishing agents. In the last few years, CNPs have been investigated for their potential applications in biomedicine as direct antioxidant therapeutic agents for the treatment of reactive oxygen species associated conditions such as cancer, chronic inflammation, and retinal degeneration, to name a few. However, very few investigations have been conducted with the aim of determining the potential for CNPs to be used as targeted drug delivery/therapeutic systems.
The hypothesis is that a novel CD44 receptor-targeted CNP drug delivery system conjugated with a cancer-specific targeting moiety (Hyaluronic acid) capable of inhibiting the proliferation and migration of highly CD44 receptor-expressed cancer cells, in particular, ovarian, breast or prostate cancer cells. Synthesis of CNPs will have better mono-dispersion with different HA-concentration functionalization and hence believe in showing better cellular uptake and inhibiting cancer cell migration.
Therefore, the aim of this study was to develop a one-pot synthesis of CNP containing HA and investigate their interaction with cancer cell lines expressing CD44 both in vitro and in vivo models.
